These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 30155674

  • 21. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET.
    Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, Mari C, Visser GWM, Valverde IE, Gasser G, Mindt TL, van Dongen GAMS.
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [Abstract] [Full Text] [Related]

  • 22. Total-Body PET and Highly Stable Chelators Together Enable Meaningful 89Zr-Antibody PET Studies up to 30 Days After Injection.
    Berg E, Gill H, Marik J, Ogasawara A, Williams S, van Dongen G, Vugts D, Cherry SR, Tarantal AF.
    J Nucl Med; 2020 Mar; 61(3):453-460. PubMed ID: 31562219
    [Abstract] [Full Text] [Related]

  • 23. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
    Cai H, Shi Q, Tang Y, Chen L, Chen Y, Tao Z, Yang H, Xie F, Wu X, Liu N, Yang Y, Wu H, Tian R, Lu X, Li L.
    Mol Pharm; 2019 May 06; 16(5):1950-1957. PubMed ID: 30986347
    [Abstract] [Full Text] [Related]

  • 24. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma.
    Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN, Chan E, Meher N, Bidlingmaier S, Su Y, Dhrona S, Geng H, Sarin V, VanBrocklin HF, Wilson DM, He J, Zhang L, Steri V, Wong SW, Martin TG, Seo Y, Liu B, Wiita AP, Flavell RR.
    Clin Cancer Res; 2024 Mar 01; 30(5):1009-1021. PubMed ID: 38109209
    [Abstract] [Full Text] [Related]

  • 25. A radiopharmaceutical [89Zr]Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo.
    Tang Y, Hu Y, Liu W, Chen L, Zhao Y, Ma H, Yang J, Yang Y, Liao J, Cai J, Chen Y, Liu N.
    Nucl Med Biol; 2019 Mar 01; 70():23-31. PubMed ID: 30826708
    [Abstract] [Full Text] [Related]

  • 26. In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.
    Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.
    Mol Cancer Ther; 2018 May 01; 17(5):1003-1011. PubMed ID: 29440294
    [Abstract] [Full Text] [Related]

  • 27. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
    Christensen C, Kristensen LK, Alfsen MZ, Nielsen CH, Kjaer A.
    Eur J Nucl Med Mol Imaging; 2020 May 01; 47(5):1302-1313. PubMed ID: 31883023
    [Abstract] [Full Text] [Related]

  • 28. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.
    Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J.
    J Nucl Med; 2011 Oct 01; 52(10):1608-15. PubMed ID: 21908391
    [Abstract] [Full Text] [Related]

  • 29. Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma.
    Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, DiPersio J, Akers W, Dehdashti F, Achilefu S, Vij R, Shokeen M.
    J Nucl Med; 2018 Feb 01; 59(2):216-222. PubMed ID: 29025987
    [Abstract] [Full Text] [Related]

  • 30. In Vitro and In Vivo Characterization of 89Zirconium-Labeled Lintuzumab Molecule.
    Allen KJH, Jiao R, Li J, Beckford-Vera DR, Dadachova E.
    Molecules; 2022 Oct 05; 27(19):. PubMed ID: 36235126
    [Abstract] [Full Text] [Related]

  • 31. Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
    Ghai A, Zheleznyak A, Mixdorf M, O'Neal J, Ritchey J, Rettig M, DiPersio J, Shokeen M, Achilefu S.
    Eur J Nucl Med Mol Imaging; 2021 May 05; 48(5):1302-1311. PubMed ID: 33179150
    [Abstract] [Full Text] [Related]

  • 32. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF, Ab O, Lanieri L, Lee J, Coccia J, Bartle LM, Themeles M, Zhou Y, Pinkas J, Ruiz-Soto R.
    Neoplasia; 2016 Dec 05; 18(12):775-784. PubMed ID: 27889646
    [Abstract] [Full Text] [Related]

  • 33. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44.
    Diebolder P, Mpoy C, Scott J, Huynh TT, Fields R, Spitzer D, Bandara N, Rogers BE.
    J Nucl Med; 2021 Jan 05; 62(1):137-143. PubMed ID: 32513906
    [Abstract] [Full Text] [Related]

  • 34. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
    Vázquez SM, Endepols H, Fischer T, Tawadros SG, Hohberg M, Zimmermanns B, Dietlein F, Neumaier B, Drzezga A, Dietlein M, Schomäcker K.
    Mol Imaging Biol; 2022 Feb 05; 24(1):115-125. PubMed ID: 34370181
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
    Azhdarinia A, Voss J, Ghosh SC, Simien JA, Hernandez Vargas S, Cui J, Yu WA, Liu Q, Carmon KS.
    Mol Pharm; 2018 Jun 04; 15(6):2448-2454. PubMed ID: 29718672
    [Abstract] [Full Text] [Related]

  • 36. CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging.
    Ulaner GA, Sobol NB, O'Donoghue JA, Kirov AS, Riedl CC, Min R, Smith E, Carter LM, Lyashchenko SK, Lewis JS, Landgren CO.
    Radiology; 2020 Jun 04; 295(3):606-615. PubMed ID: 32255416
    [Abstract] [Full Text] [Related]

  • 37. Tumor uptake and tumor/blood ratios for [89Zr]Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1.
    Al-Saden N, Cai Z, Reilly RM.
    Nucl Med Biol; 2018 Dec 04; 67():43-51. PubMed ID: 30390575
    [Abstract] [Full Text] [Related]

  • 38. In Vivo Characterization of Platinum(II)-Based Linker Technology for the Development of Antibody-Drug Conjugates: Taking Advantage of Dual Labeling with 195mPt and 89Zr.
    Muns JA, Montserrat V, Houthoff HJ, Codée-van der Schilden K, Zwaagstra O, Sijbrandi NJ, Merkul E, van Dongen GAMS.
    J Nucl Med; 2018 Jul 04; 59(7):1146-1151. PubMed ID: 29496986
    [Abstract] [Full Text] [Related]

  • 39. Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer.
    Mack KN, Samuels ZV, Carter LM, Viray TD, Mandleywala K, Brooks CL, Hollingsworth MA, Radhakrishnan P, Lewis JS.
    J Nucl Med; 2024 Apr 01; 65(4):580-585. PubMed ID: 38485271
    [Abstract] [Full Text] [Related]

  • 40. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET.
    Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J.
    Clin Cancer Res; 2021 Mar 01; 27(5):1305-1315. PubMed ID: 33293372
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.